Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-0.90% $0.720
America/New_York / 26 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 4.94 mill |
EPS: | -1.820 |
P/E: | -0.400 |
Earnings Date: | Jul 03, 2024 |
SharesOutstanding: | 6.87 mill |
Avg Daily Volume: | 0.0558 mill |
RATING 2024-04-26 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.400 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.07x |
Company: PE -0.400 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.791 (9.90%) $0.0712 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 0.621 - 0.787 ( +/- 11.79%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Ault Milton C Iii | Buy | 1 000 | Common Stock |
2024-04-01 | Ault Milton C Iii | Buy | 334 | Common Stock |
2024-01-05 | Ault Milton C Iii | Buy | 2 000 | Common Stock |
2024-03-26 | Ault Milton C Iii | Buy | 780 000 | Warrants |
2024-03-26 | Ault Milton C Iii | Buy | 780 | Series B Convertible Preferred Stock |
INSIDER POWER |
---|
-7.90 |
Last 96 transactions |
Buy: 11 786 230 | Sell: 5 921 131 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.720 (-0.90% ) |
Volume | 0.0138 mill |
Avg. Vol. | 0.0558 mill |
% of Avg. Vol | 24.75 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.